AzaFol
Phase 2Small molecule
AzaFol is one of 43 small molecule programs targeting Vasculitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
58 competitors in Vasculitis
#DrugCompanyPhaseTrials
1Plaquenil
Alnylam PharmaceuticalsApproved
Imuran
LLegacy Health System
Approved
Campath
GGenzyme, a Sanofi Company
Approved
Glucocorticoids
NovartisApproved
Colcrys
Alnylam PharmaceuticalsPhase 3
Medrol
PfizerPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Benlysta
GGlaxo Dba Glaxosmithkline
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AzaFol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details